|Bid||98.0900 x 100|
|Ask||98.1900 x 400|
|Day's Range||97.8050 - 98.1705|
|52 Week Range||77.4700 - 98.1705|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.40%|
Pfizer's Innovative Health segment contributes ~58% of PFE's total revenues and reported an operational growth of 6% to $7.4 billion for 1Q17.
Zacks Investment Ideas feature highlights: Vanguard Mega Cap Growth ETF, PowerShares Russell Top 200 Pure Growth Portfolio, iShares Global 100 ETF and SPDR Euro STOXX 50 ETF
AstraZeneca's (AZN) Oncology segment has consistently reported revenue growth over the last few years, and it's one of the company's key areas of focus.
Novartis (NVS) released its 1Q17 earnings on April 25, 2017, reporting a 25.0% rise in revenues at constant exchange rates compared to 1Q16.
AstraZeneca's (AZN) Respiratory Product sales fell 3% at constant exchange rates to ~$4.8 billion during fiscal 2016.